APA (7th ed.) Citation

Amrita Goyal, M., Damodaran Narayanan, M., Waihay Wong, M., Alvaro C. Laga, M., Nathan T. Connell, M., Susan Y. Ritter, M., & Gabriela Cobos, M. (2022). Tocilizumab for treatment of cutaneous and systemic manifestations of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome without myelodysplastic syndrome. Elsevier.

Chicago Style (17th ed.) Citation

Amrita Goyal, MD, MBBS Damodaran Narayanan, MD Waihay Wong, MD Alvaro C. Laga, MD Nathan T. Connell, MD Susan Y. Ritter, and MD Gabriela Cobos. Tocilizumab for Treatment of Cutaneous and Systemic Manifestations of Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome Without Myelodysplastic Syndrome. Elsevier, 2022.

MLA (9th ed.) Citation

Amrita Goyal, MD, et al. Tocilizumab for Treatment of Cutaneous and Systemic Manifestations of Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome Without Myelodysplastic Syndrome. Elsevier, 2022.